





ADVANCED DIGITAL DESIGN OF PHARMACEUTICAL THERAPEUTICS

From a large dataset of crystal structures to an understanding of the chemical space of pharmaceuticals

Andy Maloney (CCDC) Rebecca Mackenzie (STFC) Kevin Roberts (U. Leeds) Helen Blade (AZ) Bob Docherty (Pfizer) What if we designed drugs like we design aeroplanes?





W.S Woltosz, J. Comput. Aided Mol. Des. (2012), 26, 159-163




The evolution of digital design




The Cambridge Structural Database (CSD)





The Cambridge Structural Database (CSD)





Drug definition taken from a database of approved drugs




Extract these drugs from the CSD and create a subset that is searchable and sortable by categories such as solid form

Understand the chemical space by calculating molecular and crystallographic descriptors


Repeat that process for the in-house databases of Pfizer and AZ



The CSD Drug Subset




The CSD Drug Subset – Molecular descriptors




A D D P T

The CSD Drug Subset – Molecular descriptors






Linking molecular descriptors and solid forms





New definitions of "drug-like"?



The less intense the colour, the less sure the classifier is.


11

85% accuracy

Embedding allows us to show a 2D representation of the feature space. Molecules very 'alike' are close together in this space.



Predicting drug-likeness




The dotted line indicates random classifications. QED and Lipinski's do worse than random on this test set.

12

The higher and to the left, the better the model is at finding **known drugs**. Naïve Bayes is very good at this. The higher and to the right, the better the model is at finding '**drug-like**' – (non-drugs as drugs, whilst still finding as many known drugs). Support vector is very good at this.

28th March 2019


What else can the data tell us?



13


28th March 2019

Utilising the data – "solid form informatics"






Trends in structural features




Combining structural features






Building on the data – "particle informatics"






Trends in particle properties




From molecules to materials





Summary





Mat Bryant, Ian Bruno (CCDC) Dawn Geatches, Chris Morris (STFC) Jonathan Pickering, Ian Rosbottom, Robert Hammond (U. Leeds) Stefan Taylor (AZ) Kevin Back (Pfizer)

